This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family Foundation, a nonpartisan healthcare policy research company unaffiliated with Kaiser Permanente.. Access to lifesaving generic medications threatened by U.S. Trade pact Usage of affordable lifesaving medicines will be threatened where they are needed most – – in elements of the developing globe – – if the U.S.Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes A drug formerly used to treat your skin disorder psoriasis shows encouraging results in a phase 2 trial to assess its performance in treating type 1 diabetes, according to fresh research published in The Lancet Diabetes & Endocrinology. The problem is thought to affect around 400,000 people in the UK; patients require lifelong treatment with insulin shots, and so are at increased threat of illness and death related to their condition substantially. Trials in the 1980s and 1990s explored the chance of using immune-supressing medicines to take care of type 1 diabetes, but the risks of long-term immunosuppressant therapy outweighed the benefits. However, recently, immune-suppressing drugs have already been developed that possess a much more specific effect on the immune system cells that cause problems in autoimmune disorders, while preserving the immune cells which are crucial for normal immune functioning.